Table 3.
Top ten food and drug administration (FDA)-approved drugs in the TcDHFR-TS virtual screening based on their interaction features and free energy of binding.
| Name | Structure | Vina Score Kcal/mol | Description |
|---|---|---|---|
| Trimetrexate |
|
−8.5 | DHFR-TS inhibitor |
| Nebivolol |
|
−10.2 | Treatment of hypertension |
| Nilotinib |
|
−10.1 | Tyrosine kinase inhibitor |
| Glipizide |
|
−9.8 | Anti-diabetes drug |
| Glyburide |
|
−9.7 | Anti-diabetes drug |
| Gliquidone |
|
−9.5 | Anti-diabetes drug |
| Imatinib |
|
−9.5 | Tyrosine kinase inhibitor |
| Dihydro-alpha-ergocryptine |
|
−9.5 | Early treatment of Parkinson’s disease |
| Dihydroergocornine |
|
−9.4 | Early treatment of Parkinson’s disease |
| Darifenacin |
|
−9.4 | Treatment of urinary incontinence |
| Eltrombopag |
|
−9.3 | Treatment of chronic immune thrombocytopenia |